Institute for Clinical & Economic Review Publishes Evidence Report on Gene Therapy for Beta Thalassemia
June 03, 2022
June 03, 2022
BOSTON, Massachusetts, June 3 (TNSres) -- The Institute for Clinical and Economic Review issued the following news release on June 2, 2022:
* * *
Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassemia
Given the high costs of standard care, cost-effectiveness modeling finds beti-cel meets commonly accepted value thresholds at an anticipated price of $2.1 million with an outcomes-based agree . . .
* * *
Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassemia
Given the high costs of standard care, cost-effectiveness modeling finds beti-cel meets commonly accepted value thresholds at an anticipated price of $2.1 million with an outcomes-based agree . . .